{'fraction_non_alphanumeric': 0.016304347826086956, 'fraction_numerical': 0.0, 'mean_word_length': 5.761467889908257, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk

On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA reductase (statins) have become increasingly used in clinical practice for the prevention of cardiovascular disease. Rosuvastatin was developed as a potent statin, which appeared to raise levels of HDL-cholesterol, in addition to marked reductions in levels of LDL-cholesterol. These effects on lipids are associated with a beneficial impact of rosuvastatin on progression of various stages of atherosclerosis and cardiovascular outcomes in clinical trials. The clinical experience of rosuvastatin will be reviewed in this article.